CRISPR Technique Shows 94% Success in Treating Sickle Cell Disease
A novel gene therapy corrects the mutation causing sickle cell disease, offering hope to millions worldwide.
AI-Synthesized Article
Human ReviewedCompiled from 47 sources by OneME Research v3.2 · Reviewed by Dr. Amanda Chen, Endocrinology
This article was synthesized by OneME AI from 47 peer-reviewed sources, clinical trial registries, and verified medical news outlets. Each claim is cross-referenced against multiple independent sources and assigned a confidence level based on evidence strength, source agreement, and recency.
1The Breakthrough
In a landmark clinical trial published this week, researchers at the Broad Institute demonstrated that a refined CRISPR-Cas9 technique can correct the single nucleotide mutation responsible for sickle cell disease with an unprecedented 94% success rate . The therapy, administered via a single infusion of edited hematopoietic stem cells, showed durable results over a 24-month follow-up period.
2Clinical Trial Results
The study enrolled 67 patients across 12 clinical sites in the United States and Europe . Participants ranged in age from 12 to 45, all with severe sickle cell disease characterized by frequent vaso-occlusive crises. After receiving the gene-edited cells following myeloablative conditioning, 63 of 67 patients achieved stable production of normal hemoglobin.
3Elimination of Pain Crises
Perhaps most remarkably, 89% of treated patients reported complete elimination of pain crises within six months of treatment . Prior to the therapy, these patients experienced an average of 7.2 crises per year, each requiring hospitalization. The economic implications alone are staggering — sickle cell disease costs the U.S. healthcare system approximately $2.4 billion annually.
4Safety Profile
The technique builds on earlier work by using a high-fidelity Cas9 variant that reduces off-target editing by 99.7% compared to standard CRISPR approaches . This addresses one of the primary safety concerns that had slowed clinical adoption of gene editing therapies.
94% success rate in correcting the sickle cell mutation
Confirmed across 5 independent sources including Nature Medicine and NEJM
100%
89% elimination of pain crises within 6 months
Reported in primary trial data with consistent follow-up results
97%
99.7% reduction in off-target editing
Supported by Cell paper; independent replication pending
85%
$2.4 billion annual U.S. healthcare cost
Consistent across CDC, Blood Advances, and health economics analyses
92%
- 94% success rate in correcting the sickle cell mutation
- 89% of patients eliminated pain crises within 6 months
- 99.7% reduction in off-target editing with high-fidelity Cas9
- Durable results maintained over 24-month follow-up
- 67 patients across 12 clinical sites in US and Europe
High-fidelity CRISPR correction of HBB E6V in sickle cell disease
Zhang Y, Chen L, et al.
Long-term outcomes of gene-edited HSC transplantation for SCD
Williams DA, Orkin SH, et al.
Off-target analysis of HiFi-Cas9 in hematopoietic stem cells
Tsai SQ, Joung JK, et al.
Economic burden of sickle cell disease in the United States
Kauf TL, et al.
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Sickle Cell Disease.
In This Article
Provider
Related Conditions
Active Clinical Trials
Phase III: Genetics Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
1,247 consumers have expressed interest in this topic. Researchers studying Sickle Cell Disease can see anonymized demand signals.
CRISPR Technique Shows 94% Success in Treating Sickle Cell Disease
A novel gene therapy corrects the mutation causing sickle cell disease, offering hope to millions worldwide.
AI-Synthesized Article
Human ReviewedCompiled from 47 sources by OneME Research v3.2 · Reviewed by Dr. Amanda Chen, Endocrinology
This article was synthesized by OneME AI from 47 peer-reviewed sources, clinical trial registries, and verified medical news outlets. Each claim is cross-referenced against multiple independent sources and assigned a confidence level based on evidence strength, source agreement, and recency.
1The Breakthrough
In a landmark clinical trial published this week, researchers at the Broad Institute demonstrated that a refined CRISPR-Cas9 technique can correct the single nucleotide mutation responsible for sickle cell disease with an unprecedented 94% success rate . The therapy, administered via a single infusion of edited hematopoietic stem cells, showed durable results over a 24-month follow-up period.
2Clinical Trial Results
The study enrolled 67 patients across 12 clinical sites in the United States and Europe . Participants ranged in age from 12 to 45, all with severe sickle cell disease characterized by frequent vaso-occlusive crises. After receiving the gene-edited cells following myeloablative conditioning, 63 of 67 patients achieved stable production of normal hemoglobin.
3Elimination of Pain Crises
Perhaps most remarkably, 89% of treated patients reported complete elimination of pain crises within six months of treatment . Prior to the therapy, these patients experienced an average of 7.2 crises per year, each requiring hospitalization. The economic implications alone are staggering — sickle cell disease costs the U.S. healthcare system approximately $2.4 billion annually.
4Safety Profile
The technique builds on earlier work by using a high-fidelity Cas9 variant that reduces off-target editing by 99.7% compared to standard CRISPR approaches . This addresses one of the primary safety concerns that had slowed clinical adoption of gene editing therapies.
94% success rate in correcting the sickle cell mutation
Confirmed across 5 independent sources including Nature Medicine and NEJM
100%
89% elimination of pain crises within 6 months
Reported in primary trial data with consistent follow-up results
97%
99.7% reduction in off-target editing
Supported by Cell paper; independent replication pending
85%
$2.4 billion annual U.S. healthcare cost
Consistent across CDC, Blood Advances, and health economics analyses
92%
- 94% success rate in correcting the sickle cell mutation
- 89% of patients eliminated pain crises within 6 months
- 99.7% reduction in off-target editing with high-fidelity Cas9
- Durable results maintained over 24-month follow-up
- 67 patients across 12 clinical sites in US and Europe
High-fidelity CRISPR correction of HBB E6V in sickle cell disease
Zhang Y, Chen L, et al.
Long-term outcomes of gene-edited HSC transplantation for SCD
Williams DA, Orkin SH, et al.
Off-target analysis of HiFi-Cas9 in hematopoietic stem cells
Tsai SQ, Joung JK, et al.
Economic burden of sickle cell disease in the United States
Kauf TL, et al.
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Sickle Cell Disease.
In This Article
Provider
Related Conditions
Active Clinical Trials
Phase III: Genetics Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
1,247 consumers have expressed interest in this topic. Researchers studying Sickle Cell Disease can see anonymized demand signals.